Icosavax is developing virus-like particle (VLP) vaccines to protect vulnerable older adults from multiple respiratory viruses. This approach aims to enhance immune response, increase coverage against viral mutations, and reduce side effects compared to traditional vaccine methods.
Funding
$1.5B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Older adults are particularly vulnerable to respiratory viruses, and current vaccines may not provide sufficient protection due to weakened immune responses, viral mutations, and potential side effects. Traditional vaccine methods may also lack broad coverage against multiple respiratory viruses simultaneously.
Solution
Icosavax is a clinical-stage company developing virus-like particle (VLP) vaccines designed to protect older adults from multiple respiratory viruses. Their VLP technology mimics the structure of native viruses to stimulate a robust immune response, potentially offering advantages over existing vaccines. These advantages include a greater magnitude of response, broader coverage against viral strains and mutations, longer-lasting protection, fewer side effects, and the ability to combine multiple targets into a single vaccine. The company's pipeline focuses on creating vaccines that address the specific needs of this vulnerable population.
Target Audience
The primary target audience is vulnerable older adults who are at high risk for complications from respiratory viruses.
Features
- Utilizes virus-like particles (VLPs) to mimic the structure of viruses and enhance immune response.
- Designed for older adults who are more susceptible to respiratory viruses.
- Aims to provide broad coverage against multiple respiratory viruses, including related viral strains and mutations.
- Seeks to induce a greater magnitude of immune response compared to traditional vaccines.
- Focuses on creating vaccines with longer durability and fewer side effects.
- Employs a combinability approach to allow multiple targets in one vaccine.